SynthesisJournal of cardiothoracic surgery2026
SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes.
Synthesis in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResidual mortality and heart-failure events remain common after aortic valve intervention for severe aortic stenosis. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in heart-failure, diabetes, and chronic kidney disease populations, but their role following transcatheter or surgical aortic valve intervention remains uncertain.
methodsPubMed, Scopus, ScienceDirect, Cochrane Library, citation tracking, and manually identified eligible studies were screened through June 2026 for randomized and observational studies comparing SGLT2i with usual care or no SGLT2i after aortic valve intervention. The review was registered in PROSPERO (CRD420251059332). Eligible populations included TAVR, SAVR, and bioprosthetic aortic valve evidence where available. Adjusted hazard ratios (HRs) were pooled using random-effects models while non-HR estimates and non-comparable endpoints were summarized narratively.
resultsTwelve eligible reports were included, comprising one randomized trial and 11 observational studies. Most time-to-event estimates were reported from TAVR cohorts; two SAVR-only studies and one mixed bioprosthetic AVR study added complementary surgical and valve-durability data. In the pooled time-to-event analysis, SGLT2i use was associated with lower all-cause mortality (HR 0.69, 95% CI 0.60-0.79; I²=5%; p < 0.001). The study-defined composite clinical outcome was also lower (HR 0.68, 95% CI 0.53-0.89; I²=57%; p = 0.005), although component definitions differed across studies. Estimates for heart-failure hospitalization or exacerbation, atrial fibrillation, and acute kidney injury were not statistically significant.
conclusionsSGLT2i use after aortic valve intervention was associated with lower all-cause mortality in pooled time-to-event analysis. SAVR data were clinically informative but were not sufficiently homogeneous for separate quantitative pooling. Findings for composite, heart-failure, rhythm, renal, and valve-related outcomes remain less certain. Dedicated randomized trials are needed to confirm whether the observed association reflects a treatment effect and to define patient selection, treatment timing, and peri-procedural safety.
Indexed as
Identifiers
42919410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.